Opioid use disorder is less commonly discussed in schizophrenia than alcohol or cannabis, but the data is sobering. Population studies suggest that 7 to 15 percent of people with schizophrenia have a lifetime history of opioid use disorder — significantly higher than the general-population rate of around 2 percent. The combination is dangerous: people with both conditions have substantially elevated rates of overdose, suicide, and premature death. The good news is that opioid use disorder is one of the most treatable conditions in addiction medicine, and the medications that work — methadone, buprenorphine, and extended-release naltrexone — work just as well for people with schizophrenia as for anyone else.
Medication for opioid use disorder (buprenorphine, methadone, or naltrexone) cuts overdose mortality roughly in half and is safe and effective in people with schizophrenia.
The scale of the problem
The CDC reports that drug overdose deaths in the US exceeded 107,000 in 2022, with synthetic opioids (primarily fentanyl) involved in roughly two-thirds. People with serious mental illness are over-represented among overdose deaths — a Massachusetts cohort study by Larochelle and colleagues (Annals of Internal Medicine, 2018) found that adults with mental illness had 3 to 5 times higher overdose mortality than the general population. Within that group, schizophrenia carries particularly high risk because of the combination of medication non-adherence, social marginalisation, and high rates of polysubstance use.
How opioids interact with schizophrenia
Opioids primarily affect the mu-opioid receptor system rather than dopamine, so they do not directly trigger psychosis the way stimulants do. The harm comes through different paths:
- Overdose risk — by far the biggest. Respiratory depression from opioids is the leading cause of death.
- Sedation interactions — opioids combined with sedating antipsychotics (clozapine, quetiapine, olanzapine) substantially increase respiratory depression risk.
- Treatment disengagement — active opioid use is one of the strongest predictors of psychiatric care dropout.
- Withdrawal — destabilising for sleep, mood, and symptoms; often a trigger for relapse.
- Constipation — combined with the constipating effect of clozapine and many other antipsychotics, can become medically serious.
See our broader article on opioids and antipsychotics for the pharmacology.
The three approved medications
Buprenorphine (Suboxone, Sublocade)
A partial mu-opioid agonist. Reduces cravings and withdrawal without producing the euphoria of full agonists. Available as a daily sublingual film (often combined with naloxone) or as a monthly extended-release injection (Sublocade). Can be prescribed by any clinician with a valid DEA registration since the X-waiver was eliminated in 2023, dramatically expanding access. Generally safe alongside antipsychotics, with the caveat about combined sedation. The SAMHSA buprenorphine page covers details.
Methadone
A full mu-opioid agonist. Highly effective for severe opioid use disorder, including for people with high tolerance. Can only be dispensed through federally licensed opioid treatment programs (OTPs), which require daily visits during the first months. Has more significant interactions than buprenorphine — including QT prolongation, which matters when combined with antipsychotics that also prolong QT (see QT prolongation article).
Extended-release naltrexone (Vivitrol)
An opioid receptor antagonist given as a monthly injection. Blocks the effects of opioids if the person uses. Works only after a complete opioid washout (typically 7 to 10 days), which is the main barrier to starting it. No abuse liability and no sedation interaction with antipsychotics. Effective for motivated patients in supportive environments.
The evidence in schizophrenia specifically
A growing body of research, summarised by NIDA and the SAMHSA disorders portal, shows that medication for opioid use disorder works as well in people with schizophrenia as in the general population. Buprenorphine, in particular, has been shown to be safe and effective alongside common antipsychotics. The most successful programs combine medication with case management, often through assertive community treatment, integrated dual-diagnosis programs, or coordinated specialty care.
Naloxone (Narcan): the single most important intervention
Naloxone reverses opioid overdose within minutes when administered correctly. It is now available over the counter in all 50 US states and is distributed free by many harm-reduction agencies. Train at least one person who is around you (family member, peer worker, roommate) on how to use it. The CDC's Stop Overdose page has training resources.
Fentanyl test strips and harm reduction
Roughly 75 percent of US opioid overdose deaths now involve fentanyl, which is increasingly contaminating heroin, counterfeit pills, and even non-opioid drugs (cocaine, methamphetamine, MDMA). Fentanyl test strips allow users to check their supply. They are now legal in most states and available free from harm-reduction programs. Other harm-reduction practices include not using alone, going slowly with a new supply, and having naloxone within reach. See our broader article on harm reduction.
Practical steps if you use opioids and have schizophrenia
- Tell your psychiatrist. Most are not shocked and can help connect you to MOUD (medication for opioid use disorder).
- Find a buprenorphine prescriber. SAMHSA's treatment locator identifies prescribers near you.
- If you cannot get to a buprenorphine prescriber, look for a methadone clinic (Opioid Treatment Program).
- Get naloxone today and carry it.
- Get fentanyl test strips and use them every time.
- Don't use alone. The single biggest predictor of fatal overdose is using when no one else is around.
- Discuss your sedating antipsychotic dose with your prescriber — combined sedation matters.
For families
Family training (CRAFT) and Al-Anon/Nar-Anon meetings help families maintain connection without losing themselves. Family carrying naloxone has saved many lives. The when loved one refuses treatment article is also worth reading.
The integrated treatment model
For schizophrenia + opioid use disorder, the highest-impact model is integrated care: a single team that prescribes the antipsychotic, prescribes buprenorphine, manages housing and benefits, and provides case management. See our article on integrated dual disorder treatment. Where this is not available locally, building a coordinated team across several agencies — with one identified case manager who keeps the parts talking — is the workable substitute.
The bigger picture
Opioid use disorder is among the most lethal psychiatric comorbidities and one of the most treatable. The medications work. The science is settled. The barriers are now mostly access, stigma, and clinicians who do not know what they don't know. If you have schizophrenia and use opioids, the path forward is real — and starts with medication, naloxone, and a relationship with someone who treats both conditions seriously.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.